NBI-1117570
DrugOral administration
NCT Number: NCT07288333
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Phase 2
Neurocrine Clinical Site, Kazanlak, Bulgaria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Oral administration
Oral administration
Time frame: Day 35
Time frame: Day 1 up to Day 49
Contact information is provided by the study sponsor or research team.
Neurocrine Biosciences
Industry
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07369154
Mental Disorders, Schizophrenia
Chandler, Arizona, United States
View Trial DetailsNCT07411222
Behavior, Bipolar Disorder
Bolu, Turkey (Türkiye)
View Trial DetailsNCT06882785
Mental Disorders, Schizophrenia
Kōnan, Aichi-ken, Japan
View Trial DetailsNCT07363577
Mental Disorders, Schizophrenia
Bentonville, Arkansas, United States
View Trial Details